SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan.
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$54.60|
|52 Week High||NT$45.80|
|52 Week Low||NT$73.20|
|1 Month Change||-3.19%|
|3 Month Change||1.49%|
|1 Year Change||-21.44%|
|3 Year Change||-24.37%|
|5 Year Change||-2.17%|
|Change since IPO||66.73%|
Recent News & Updates
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?
We believe investing is smart because history shows that stock markets go higher in the long term. But if you choose...
|1786||TW Medical Equipment||TW Market|
Return vs Industry: 1786 underperformed the TW Medical Equipment industry which returned 5.3% over the past year.
Return vs Market: 1786 underperformed the TW Market which returned 34% over the past year.
Stable Share Price: 1786 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 1786's weekly volatility (3%) has been stable over the past year.
About the Company
|2001||n/a||Tai Xian Han||https://www.scivision.com.tw|
SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. It offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. The company was founded in 2001 and is based in Kaohsiung, Taiwan.
SciVision Biotech Fundamentals Summary
|1786 fundamental statistics|
Is 1786 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1786 income statement (TTM)|
|Cost of Revenue||NT$135.09m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||2.06|
|Net Profit Margin||25.58%|
How did 1786 perform over the long term?See historical performance and comparison
1.8%Current Dividend Yield
Does 1786 pay a reliable dividends?See 1786 dividend history and benchmarks
|SciVision Biotech dividend dates|
|Ex Dividend Date||Oct 04 2021|
|Dividend Pay Date||Oct 29 2021|
|Days until Ex dividend||10 days|
|Days until Dividend pay date||35 days|
Does 1786 pay a reliable dividends?See 1786 dividend history and benchmarks
Is SciVision Biotech undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 1786 (NT$54.6) is trading above our estimate of fair value (NT$20.56)
Significantly Below Fair Value: 1786 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 1786 is poor value based on its PE Ratio (26.5x) compared to the TW Medical Equipment industry average (23.1x).
PE vs Market: 1786 is poor value based on its PE Ratio (26.5x) compared to the TW market (16.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1786's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1786 is overvalued based on its PB Ratio (2.3x) compared to the TW Medical Equipment industry average (2x).
How is SciVision Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SciVision Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has SciVision Biotech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1786 has high quality earnings.
Growing Profit Margin: 1786's current net profit margins (25.6%) are lower than last year (27.8%).
Past Earnings Growth Analysis
Earnings Trend: 1786's earnings have grown significantly by 45.1% per year over the past 5 years.
Accelerating Growth: 1786's earnings growth over the past year (1.1%) is below its 5-year average (45.1% per year).
Earnings vs Industry: 1786 earnings growth over the past year (1.1%) underperformed the Medical Equipment industry 9.5%.
Return on Equity
High ROE: 1786's Return on Equity (8.6%) is considered low.
How is SciVision Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: 1786's short term assets (NT$867.3M) exceed its short term liabilities (NT$421.9M).
Long Term Liabilities: 1786's short term assets (NT$867.3M) exceed its long term liabilities (NT$398.2M).
Debt to Equity History and Analysis
Debt Level: 1786's debt to equity ratio (41.1%) is considered high.
Reducing Debt: 1786's debt to equity ratio has increased from 26.3% to 41.1% over the past 5 years.
Debt Coverage: 1786's debt is well covered by operating cash flow (21.5%).
Interest Coverage: 1786's interest payments on its debt are well covered by EBIT (22.1x coverage).
What is SciVision Biotech current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 1786's dividend (1.76%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (1.96%).
High Dividend: 1786's dividend (1.76%) is low compared to the top 25% of dividend payers in the TW market (5.31%).
Stability and Growth of Payments
Stable Dividend: 1786 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 1786's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (46.6%), 1786's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Tai Xian Han
Tai Xian Han serves as a General Manager of Scivision Biotech Inc and serves as its Director.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
SciVision Biotech Inc.'s employee growth, exchange listings and data sources
- Name: SciVision Biotech Inc.
- Ticker: 1786
- Exchange: TWSE
- Founded: 2001
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: NT$3.331b
- Shares outstanding: 61.01m
- Website: https://www.scivision.com.tw
- SciVision Biotech Inc.
- 9, South 6th Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 16:02|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.